Overview

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Status:
Active, not recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)

Phase:

Phase 2

Details

Lead Sponsor:

Hoosier Cancer Research Network

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab